JPWO2022270523A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022270523A5
JPWO2022270523A5 JP2022542937A JP2022542937A JPWO2022270523A5 JP WO2022270523 A5 JPWO2022270523 A5 JP WO2022270523A5 JP 2022542937 A JP2022542937 A JP 2022542937A JP 2022542937 A JP2022542937 A JP 2022542937A JP WO2022270523 A5 JPWO2022270523 A5 JP WO2022270523A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022542937A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022270523A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/024812 external-priority patent/WO2022270523A1/ja
Publication of JPWO2022270523A1 publication Critical patent/JPWO2022270523A1/ja
Publication of JPWO2022270523A5 publication Critical patent/JPWO2022270523A5/ja
Pending legal-status Critical Current

Links

JP2022542937A 2021-06-23 2022-06-22 Pending JPWO2022270523A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021103818 2021-06-23
PCT/JP2022/024812 WO2022270523A1 (ja) 2021-06-23 2022-06-22 癌の治療及び/又は予防のための医薬品

Publications (2)

Publication Number Publication Date
JPWO2022270523A1 JPWO2022270523A1 (https=) 2022-12-29
JPWO2022270523A5 true JPWO2022270523A5 (https=) 2025-06-20

Family

ID=84545727

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022542937A Pending JPWO2022270523A1 (https=) 2021-06-23 2022-06-22

Country Status (10)

Country Link
US (1) US20240325529A1 (https=)
EP (1) EP4360648A4 (https=)
JP (1) JPWO2022270523A1 (https=)
KR (1) KR20240024074A (https=)
CN (1) CN117545508A (https=)
AU (1) AU2022296193A1 (https=)
BR (1) BR112023026985A2 (https=)
CA (1) CA3225420A1 (https=)
MX (1) MX2023014498A (https=)
WO (1) WO2022270523A1 (https=)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE69535243T2 (de) 1994-07-13 2007-05-10 Chugai Seiyaku K.K. Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
DK1069185T3 (da) 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
BRPI0911926A2 (pt) 2008-08-05 2020-08-18 Toray Industries, Inc composições farmacêuticas, anticorpos e usos de um anticorpo ou um fragmento do mesmo.
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
DK2532680T3 (da) 2010-02-04 2015-07-20 Toray Industries Medicinsk sammensætning til behandling og/eller forebyggelse af cancer
HUE040012T2 (hu) 2010-02-04 2019-02-28 Toray Industries Gyógyászati ágens rák kezelésére és/vagy megelõzésére
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
US9115200B2 (en) 2010-02-04 2015-08-25 Toray Industries, Inc. Pharmaceutical composition for treating cancer using a monoclonal antibody having immunological reactivity with CAPRIN-1
CA2788545C (en) 2010-02-04 2019-03-26 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
JP2013528357A (ja) 2010-03-29 2013-07-11 ザイムワークス,インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740796T (pt) 2011-08-04 2017-07-26 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
PL2740793T3 (pl) 2011-08-04 2018-04-30 Toray Industries, Inc. Kompozycja leku do leczenia i/lub zapobiegania nowotworowi
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
ES2739612T3 (es) 2012-02-21 2020-02-03 Toray Industries Composición farmacéutica para el tratamiento de cáncer
WO2013125654A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び/又は予防用医薬組成物
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
JP6107654B2 (ja) 2012-03-30 2017-04-05 東レ株式会社 肝臓癌の治療及び/又は予防用医薬組成物
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び/又は予防用医薬組成物
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
AU2014303375B2 (en) 2013-08-09 2019-07-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
AU2019242520B2 (en) * 2018-03-30 2026-02-26 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer

Similar Documents

Publication Publication Date Title
US20230115328A1 (en) Anti-B7-H1 and Anti-CTLA-4 Antibodies for Treating Non-Small Cell Lung Cancer
KR102349056B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
Milette et al. Molecular pathways: targeting the microenvironment of liver metastases
Yan et al. HER2 aberrations in cancer: implications for therapy
JP2025029025A (ja) 抗pd-1抗体および抗ctla-4抗体の組合せを用いる肺癌の処置法
JP2018070648A5 (https=)
JP2018518454A5 (https=)
JP2020503273A5 (https=)
JP7797875B2 (ja) 癌の治療及び/又は予防のための医薬品
JP2008531576A5 (https=)
JP2025092589A5 (https=)
JP2016520082A5 (https=)
CN107635583A (zh) 用于治疗癌症的方法、组合物和试剂盒
JP2021511372A5 (https=)
JP2017534574A (ja) チロシンキナーゼ阻害薬(tki)に耐性のがんを処置するための組成物および方法
JPWO2022270524A5 (https=)
ES2328159T3 (es) Inmunoglobulinas anti-epcam.
CN111867598A (zh) 肿瘤免疫赋活剂
JPWO2022270523A5 (https=)
Roca et al. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer
JPWO2023008462A5 (https=)
WO2022270523A1 (ja) 癌の治療及び/又は予防のための医薬品
RU2024101376A (ru) Лекарственное средство для лечения и/или профилактики злокачественной опухоли
JPWO2023008461A5 (https=)
HK40103363A (zh) 用於治疗癌症的涉及针对密蛋白18.2的抗体的组合治疗